Published in Medical Letter on the CDC and FDA, December 5th, 2004
Hyponatremia is a potentially life-threatening condition that occurs when the body's sodium level falls below normal. The results of two, phase III studies were presented this weekend at the annual meeting of the American Society of Nephrology.
Conivaptan is a novel drug that blocks both V1A and V2 vasopressin receptors, increasing serum sodium and urine output without increasing sodium loss. This effect, known as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.